We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen is facing more bad news regarding possible off-label uses of its drug Aranesp, after independent study results pointed to adverse outcomes for a certain class of cancer patients prescribed the drug. Read More
Amgen plans to announce results from an Aranesp small-cell lung cancer clinical trial when the firm reports first-quarter earnings April 23, the company said.
A new report by the UK’s Royal Statistical Society (RSS) proposes sweeping reforms aimed at minimizing the risk to volunteers in drug trials, maximizing design efficiency and enhancing scrutiny of clinical trial protocols.
A key committee is recommending that the Centers for Medicare & Medicaid Services (CMS) soften a controversial proposal to require clinical trials it covers to enroll representatives of the populations Medicare serves.
Industry involvement in breast cancer trials may affect study design, focus and results, according to an article published in the online version of the journal Cancer.
Children under 5 immunized with FluMist had 55 percent fewer cases of influenza compared with children who received the flu shot, according to a new study.
All “unanticipated problems” affecting participants in clinical trials sponsored or supported by the U.S. Department of Health and Human Services must be reported, a new guidance from the Office for Human Research Protections (OHRP) says.
Starpharma signed a funding agreement this week with several federal agencies for further study of VivaGel, an HIV and genital herpes prevention drug, in sexually active women.
A UK governmental commission has called for the establishment of an open-access database of information for certain high-risk Phase I clinical trials, along with 21 other recommendations that are intended to prevent any repeat of the catastrophic Phase I clinical trial of gene therapy TGN1412.
VaxGen said that HHS has terminated for default the company’s $877.5 million contract to provide 75 million doses of a modern anthrax vaccine for civilian biodefense.